# Wegovy

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/wegovy-company
Canonical HTML page: https://getbiobrief.com/entity/wegovy-company

## Timeline

- **2026-07-01**: Medicare GLP-1 Bridge pilot launches — CMS begins covering Wegovy and Zepbound for weight loss under a temporary pilot, offering potential $50 copays for eligible beneficiaries instead of $1,000+ list prices.

## Recent coverage (1 stories)

### Medicare's $50 Wegovy Pilot: How 1M+ Enrollees Fuel GLP-1 Sales Boom
2026-07-21 23:50:43 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Medicare's GLP-1 Bridge pilot, starting July 1, will provide millions of enrollees with access to Wegovy and Zepbound at $50/month, potentially driving blockbuster sales for Novo Nordisk and Eli Lilly while intensifying pricing scrutiny.
Full story: https://getbiobrief.com/story/medicare-glp1-pilot-pharma-sales-wegovy-zepbound

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.